DA
CHRS icon

Duality Advisers’s Coherus Oncology CHRS Stock Holding History

Duality Advisers’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-54,489
Closed -$870K – 656
2021
Q4 		$870K Buy
+54,489
New +$953K 0.09% 319
2021
Q2 		– Sell
-49,059
Closed -$717K – 556
2021
Q1 		$717K Sell
49,059
-43,552
-47% -$739K 0.06% 401
2020
Q4 		$1.61M Buy
92,611
+41,381
+81% +$737K 0.12% 260
2020
Q3 		$940K Buy
+51,230
New +$953K 0.06% 384

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Duality Advisers's CHRS Position: Q1 2022 in Review

Duality Advisers sold out of Coherus Oncology (CHRS) in Q1 2022, closing a stake of 54,489 shares — an estimated $870K sold.

Duality Advisers first reported a position in CHRS in Q3 2020 and held it in 4 quarters. The position peaked at $1.61M in Q4 2020. 183 funds tracked by Wall St. Rank hold CHRS as of Q1 2022.

  • Duality Advisers reported no remaining Coherus Oncology position as of Q1 2022 after selling out during the quarter.
  • Duality Advisers sold 54,489 Coherus Oncology shares in Q1 2022, an estimated $870K.
  • Duality Advisers first reported a position in Coherus Oncology in Q3 2020 and held it in 4 quarters.
  • Duality Advisers's Coherus Oncology position peaked at $1.61M in Q4 2020.
  • 183 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2022.

Based on Duality Advisers's 13F filing for Q1 2022, filed 9 May 2022.